Table 1. p53 analysis and IGVH gene... | American Society of Hematology

Table 1.

p53 analysis and IGVH gene status

Patient	Chromosome abnormality	FISH	Flow % positive cells	Sequence analysis				V genes (% homology)	Survival (mo)
Patient	Chromosome abnormality	FISH	Flow % positive cells	Exon	Codon	Nucleotide	Amino acid	V genes (% homology)	Survival (mo)
1	i17q	+−	NT			NT		100	20
2	i17q	+−	57	8	273	CGT > TGT	Arg → Cys	100	109
3	t17p13	+−	25	7	248	CGG > CAG	Arg → Gln	100	53
4	t17p13	+−	6	7	250	1-bp ins	Frameshift	100	42
5	t17p13	+−	93	5	158	CGC > GGC	Arg → Gly	100	31
6	t17p13	+−	73	5	138	GCC > CCC	Ala → Pro	100	32
7	t17q	++	90	7	248	CGG > CAG	Arg → Gln	100	21
14^*	del17p	+−	NT	7	248	CGG > GGG	Arg → Gly	100	28
15^*	Normal	NT	NT	5	163	TAC > TGC	Tyr → Cys	100	96
8	t17p13	+−	55	3	22	CTA > CTG	Silent	97	80 (alive)
9	t17p13	+−	15			NAD		97	66
10	t17p13	+−	90	5	141	TGC > CGC	Cys → Arg	95	45
11^*	NT	+−	NT	6	281	GAC > GAA	Asp → Glu	91	21 (alive)
12	r17	NT	60	5	162	ATC > AAC	Ile → Asn	91	58
13	t17p13	+−	16			NAD		91	79 (alive)

Patient	Chromosome abnormality	FISH	Flow % positive cells	Sequence analysis				V genes (% homology)	Survival (mo)
Patient	Chromosome abnormality	FISH	Flow % positive cells	Exon	Codon	Nucleotide	Amino acid	V genes (% homology)	Survival (mo)
1	i17q	+−	NT			NT		100	20
2	i17q	+−	57	8	273	CGT > TGT	Arg → Cys	100	109
3	t17p13	+−	25	7	248	CGG > CAG	Arg → Gln	100	53
4	t17p13	+−	6	7	250	1-bp ins	Frameshift	100	42
5	t17p13	+−	93	5	158	CGC > GGC	Arg → Gly	100	31
6	t17p13	+−	73	5	138	GCC > CCC	Ala → Pro	100	32
7	t17q	++	90	7	248	CGG > CAG	Arg → Gln	100	21
14^*	del17p	+−	NT	7	248	CGG > GGG	Arg → Gly	100	28
15^*	Normal	NT	NT	5	163	TAC > TGC	Tyr → Cys	100	96
8	t17p13	+−	55	3	22	CTA > CTG	Silent	97	80 (alive)
9	t17p13	+−	15			NAD		97	66
10	t17p13	+−	90	5	141	TGC > CGC	Cys → Arg	95	45
11^*	NT	+−	NT	6	281	GAC > GAA	Asp → Glu	91	21 (alive)
12	r17	NT	60	5	162	ATC > AAC	Ile → Asn	91	58
13	t17p13	+−	16			NAD		91	79 (alive)

NT indicates not tested; NAD, no abnormality detected; ++, 2 signals; +−, 1 signal.

Indicates patients who were tested by NIRCA.